SCM
TARA icon

Sterling Capital Management’s Protara Therapeutics TARA Stock Holding History

Sterling Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.87K Sell
1,703
-329
-16% -$1.95K ﹤0.01% 2438
2025
Q4 		$10.8K Sell
2,032
-197
-9% -$1.09K ﹤0.01% 2565
2025
Q3 		$9.7K Buy
2,229
+1,357
+156% +$4.39K ﹤0.01% 2500
2025
Q2 		$2.64K Buy
+872
New +$3.01K ﹤0.01% 2838

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Sterling Capital Management's TARA Position: Q1 2026 in Review

Sterling Capital Management reduced its Protara Therapeutics (TARA) stake by 16% in Q1 2026, selling an estimated $1.95K and leaving 1,703 shares worth $8.87K. The position accounts for ﹤0.01% of the portfolio, ranked #2438.

Sterling Capital Management first reported a position in TARA in Q2 2025 and has held it in 4 quarters since. The position peaked at $10.8K in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Sterling Capital Management held 1,703 shares of Protara Therapeutics worth $8.87K as of Q1 2026.
  • Sterling Capital Management sold 329 Protara Therapeutics shares in Q1 2026, an estimated $1.95K.
  • Protara Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2438 holding.
  • Sterling Capital Management first reported a position in Protara Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Sterling Capital Management's Protara Therapeutics position peaked at $10.8K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.